Related Experiment Videos
Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an
V Marco1, M Gobernado, M Santos
1Servicio de Neumología Hospital La Fe, Valencia, Spain.
Abstract:
Gram-negative pneumonia is a frequent complication in hospitalized patients, particularly in those with diminished defenses. The severity of the infections makes it necessary to start immediately an empirical antimicrobial therapy that usually combines a broad-spectrum beta-lactam antibiotic with an aminoglycoside (AMG), despite the potential toxicity of this regimen. We have compared the efficacy of a new beta-lactam antibiotic, aztreonam, which shows both a specific spectrum of activity against gram-negative bacteria and a very good diffusion into pulmonary tissue, with that of another antibiotic regimen including an AMG. Of a total of 69 patients, 43 were treated with aztreonam and the remaining patients with an AMG. Both groups were comparable with respect to the severity of infection and underlying pathology. Clinical efficacy was similar in the two regimens (81% aztreonam, 62% AMG). However, antimicrobial efficacy was superior in the aztreonam group (88% aztreonam, 65% AMG), although differences disappeared in patients treated with the combination amikacin + cefotaxime or ticarcillin in the AMG group. Colonization/superinfection was also similar in both groups, although the selection of gram-negative bacteria occurred more frequently in the AMG group. Our results suggest that aztreonam, in monotherapy, may be a useful alternative for the treatment of gram-negative pneumonia.
Insights
Aztreonam monotherapy shows promise for treating gram-negative pneumonia, offering comparable clinical efficacy to aminoglycoside regimens with improved antimicrobial effectiveness. This suggests aztreonam as a valuable alternative, especially for patients with weakened immune systems.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Gram-negative pneumonia is a common, severe complication in hospitalized patients, often requiring empirical broad-spectrum antibiotic therapy.
- Current empirical regimens combine beta-lactams with aminoglycosides (AMG), despite potential toxicity.
- Aztreonam, a beta-lactam with specific gram-negative activity and good lung penetration, offers a potential alternative.
Purpose of the Study:
- To compare the clinical and antimicrobial efficacy of aztreonam monotherapy versus an aminoglycoside-containing regimen for gram-negative pneumonia.
Main Methods:
- A comparative study involving 69 hospitalized patients with gram-negative pneumonia.
- Patients were treated with either aztreonam (43 patients) or an aminoglycoside (AMG) regimen (26 patients).
- Clinical and antimicrobial efficacy, colonization, and superinfection rates were assessed and compared between groups.
Main Results:
- Clinical efficacy was similar between aztreonam (81%) and AMG (62%) groups.
- Antimicrobial efficacy was superior in the aztreonam group (88%) compared to the AMG group (65%).
- Gram-negative bacteria selection occurred more frequently in the AMG group, with similar colonization/superinfection rates.
Conclusions:
- Aztreonam monotherapy demonstrates comparable clinical efficacy and superior antimicrobial efficacy for gram-negative pneumonia.
- Aztreonam may serve as a useful alternative treatment option, potentially reducing the toxicity associated with AMG combinations.